Novo Nordisk’s Phase 3 Zeus trial of IL-6 inhibitor ziltivekimab failed to improve outcomes in a broad cardiovascular inflammation population, according to the company’s update. While the drug demonstrated target engagement—including pathway inhibition and reduction in high-sensitivity C-reactive protein—there was no significant difference versus placebo on major adverse cardiovascular events risk reduction. The trial update adds pressure to the broader inflammation-in-cardiovascular-disease hypothesis, with investors watching whether similar mechanisms face headwinds in late-stage development.